Thera-SAbDab

CIXUTUMUMAB

>   Structural Summary
TherapeuticCixutumumab
TargetIGF1R
Heavy ChainEVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCARAPLRFLEWSTQDHYYYYYMDVWGKGTTVTVSS
Light ChainSSELTQDPAVSVALGQTVRITCQGDSLRSYYATWYQQKPGQAPILVIYGENKRPSGIPDRFSGSSSGNTASLTITGAQAEDEADYYCKSRDGSGQHLVFGGGTKLTVL
100% seqID Fv StructureNone
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb
IsotypeG1
Highest Clinical Trial (June '19)Phase-II
Estimated Status (June '19)Discontinued
Recorded Developmental TechnologyDyax Human Phage Display
INN Year Proposed2008
INN Year Recommended2009
Companies InvolvedEli Lilly, ImClone Systems, M. D. Anderson Cancer Center, National Cancer Institute (USA)
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedBreast cancer, Colorectal cancer, Head and neck cancer, Liver cancer, Neuroendocrine tumours, Non-small cell lung cancer, Oesophageal cancer, Pancreatic cancer, Prostate cancer, Rhabdomyosarcoma, Sarcoma, Soft tissue sarcoma, Solid tumours, Thymoma
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]